CLUSTER INDIVIDUALISIERTE IMMUNINTERVENTION (CI3) EV

Their core work

Ci3 is a German life sciences cluster association based in Mainz — a major European biotech hub — that organizes and supports SMEs working in personalized medicine, immunotherapy, and biomedical technology. In H2020, they participated in projects aimed at digitizing enterprise processes for biomedical SMEs, covering areas such as bioimaging, biosensing, and biobanking. Their cluster role means they act as a network node: connecting SME members with digital innovation programs, cross-sectoral partnerships, and EU funding opportunities. They bring industry proximity and SME mobilization capacity rather than hands-on lab research.

What they specialise in

How they've shifted over time

In their first project (PERMIDES, 2016–2018), Ci3 focused on the broad challenge of personalised medicine and what digital tools can do for enterprise-level innovation — no specific technology vertical was dominant. By their second project (DIGI-B-CUBE, 2019–2022), the focus had sharpened considerably: specific biomedical verticals (bioimaging, biosensing, biobanking) replaced the general framing, and keywords explicitly named the medical diagnostics value chain and ICT-driven SME growth. The overall direction is a move from broad digital-health convergence toward precision diagnostics infrastructure and the commercial ecosystems around it.

Ci3 is moving toward becoming a specialized cluster for SMEs in the diagnostics and precision medicine technology supply chain, with ICT integration as the connecting thread — making them a useful partner for digital health consortia targeting biomedical industry actors.

How they like to work

Ci3 has participated in all projects as a partner, never as coordinator — consistent with a cluster association that contributes SME mobilization and sector networks rather than leading technical work packages. With 13 unique partners across 7 countries in just 2 projects, their consortia are moderately diverse, suggesting they are brought in for their network breadth rather than deep technical specialization. For a potential collaborator, this means Ci3 is most valuable in roles involving SME engagement, dissemination, and cross-sector brokerage.

Ci3 has built connections with 13 unique partners spanning 7 countries through just 2 projects — a relatively broad network for a small association. Their geographic spread suggests a European outlook despite their regional Mainz base.

What sets them apart

Ci3 occupies an unusual niche: an immunology and personalised medicine cluster that has consistently oriented its EU project work toward digital enterprise transformation for biomedical SMEs — rather than the pure-science or clinical angles typical of similar organizations. Based in Mainz, they sit in one of Europe's densest pharma and biotech ecosystems (BioNTech's home city), which gives them direct access to a relevant SME and spin-off community. For consortium builders, this means Ci3 can deliver SME participants and industry dissemination channels in a sector that is otherwise hard to mobilize.

Highlights from their portfolio

• DIGI-B-CUBE
  The larger of the two projects (EUR 330,023, running to 2022) and the one that crystallized Ci3's focus on diagnostics — bioimaging, biosensing, and biobanking — making it the clearest signal of where their expertise now sits.
• PERMIDES
  Their entry into H2020 (2016–2018) and the project most directly tied to their founding mission of personalised medicine, establishing the link between their immunology cluster mandate and digital innovation programmes.